Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1975 1
1980 1
1981 1
1984 1
1990 1
1994 2
1995 3
1996 2
1997 4
1998 3
1999 5
2000 3
2001 4
2002 6
2003 4
2004 7
2005 3
2006 7
2007 7
2008 6
2009 8
2010 12
2011 13
2012 16
2013 16
2014 19
2015 14
2016 23
2017 22
2018 28
2019 25
2020 3
Text availability
Article attribute
Article type
Publication date

Search Results

236 results
Results by year
Filters applied: . Clear all
Page 1
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease.
Ataga KI, Kutlar A, Kanter J, Liles D, Cancado R, Friedrisch J, Guthrie TH, Knight-Madden J, Alvarez OA, Gordeuk VR, Gualandro S, Colella MP, Smith WR, Rollins SA, Stocker JW, Rother RP. Ataga KI, et al. N Engl J Med. 2017 Feb 2;376(5):429-439. doi: 10.1056/NEJMoa1611770. Epub 2016 Dec 3. N Engl J Med. 2017. PMID: 27959701 Free PMC article. Clinical Trial.
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that are involved in the pathogenesis of vaso-occlusion and sickle cell-related pain crises. ...Patients who were receiving concomi …
BACKGROUND: The up-regulation of P-selectin in endothelial cells and platelets contributes to the cell-cell interactions that …
Domain-focused CRISPR screen identifies HRI as a fetal hemoglobin regulator in human erythroid cells.
Grevet JD, Lan X, Hamagami N, Edwards CR, Sankaranarayanan L, Ji X, Bhardwaj SK, Face CJ, Posocco DF, Abdulmalik O, Keller CA, Giardine B, Sidoli S, Garcia BA, Chou ST, Liebhaber SA, Hardison RC, Shi J, Blobel GA. Grevet JD, et al. Science. 2018 Jul 20;361(6399):285-290. doi: 10.1126/science.aao0932. Science. 2018. PMID: 30026227 Free PMC article.
Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to patients with sickle cell disease and some forms of β-thalassemia. ...Taken together, these results suggest HRI as a potential therapeutic target for hemoglobinopathies
Increasing fetal hemoglobin (HbF) levels in adult red blood cells provides clinical benefit to patients with sickle cell disea …
Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
Estcourt LJ, Fortin PM, Hopewell S, Trivella M, Wang WC. Estcourt LJ, et al. Cochrane Database Syst Rev. 2017 Jan 17;1(1):CD003146. doi: 10.1002/14651858.CD003146.pub3. Cochrane Database Syst Rev. 2017. PMID: 28094851 Free PMC article. Review.
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Stroke affects around 10% of children with sickle cell anaemia (HbSS). ...AUTHORS' CONCLUSIONS: There is no evidence for managing adu
Sickle cell disease can cause severe pain, significant end-organ damage, pulmonary complications, and premature death. Stroke
Physician knowledge and adherence to prescribing antibiotic prophylaxis for sickle cell disease.
Wurst KE, Sleath BL. Wurst KE, et al. Int J Qual Health Care. 2004 Jun;16(3):245-51. doi: 10.1093/intqhc/mzh033. Int J Qual Health Care. 2004. PMID: 15150156
OBJECTIVE: The purpose of this research was to examine how physician characteristics were associated with: (i). physician knowledge of and adherence to sickle cell guidelines; and (ii). the types of educational programs about sickle cell disease desire …
OBJECTIVE: The purpose of this research was to examine how physician characteristics were associated with: (i). physician knowledge of and a …
New film-coated tablet formulation of deferasirox is well tolerated in patients with thalassemia or lower-risk MDS: Results of the randomized, phase II ECLIPSE study.
Taher AT, Origa R, Perrotta S, Kourakli A, Ruffo GB, Kattamis A, Goh AS, Cortoos A, Huang V, Weill M, Merino Herranz R, Porter JB. Taher AT, et al. Am J Hematol. 2017 May;92(5):420-428. doi: 10.1002/ajh.24668. Epub 2017 Feb 18. Am J Hematol. 2017. PMID: 28142202 Free PMC article. Clinical Trial.
Adherence to hydroxyurea, health-related quality of life domains, and patients' perceptions of sickle cell disease and hydroxyurea: a cross-sectional study in adolescents and young adults.
Badawy SM, Thompson AA, Lai JS, Penedo FJ, Rychlik K, Liem RI. Badawy SM, et al. Health Qual Life Outcomes. 2017 Jul 5;15(1):136. doi: 10.1186/s12955-017-0713-x. Health Qual Life Outcomes. 2017. PMID: 28679417 Free PMC article.
BACKGROUND: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea is safe and efficacious in SCD; however, adherence is suboptimal, and patients' perceptions are poorly understood amongst adolescents a …
BACKGROUND: Sickle cell disease (SCD) patients have impaired domains of health-related quality of life (HRQOL). Hydroxyurea
New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo?
Oder E, Safo MK, Abdulmalik O, Kato GJ. Oder E, et al. Br J Haematol. 2016 Oct;175(1):24-30. doi: 10.1111/bjh.14264. Epub 2016 Sep 8. Br J Haematol. 2016. PMID: 27605087 Free PMC article. Review.
The hallmark of sickle cell disease is the polymerization of sickle haemoglobin due to a point mutation in the β-globin gene (HBB). ...The aromatic aldehyde, 5-hydroxymethylfurfural (5-HMF) increases oxygen affinity of sickle haemoglobin and reduces hy …
The hallmark of sickle cell disease is the polymerization of sickle haemoglobin due to a point mutation in the β-globin …
Headache and Facial Pain in Sickle Cell Disease.
Vgontzas A, Charleston L 4th, Robbins MS. Vgontzas A, et al. Curr Pain Headache Rep. 2016 Mar;20(3):20. doi: 10.1007/s11916-016-0546-z. Curr Pain Headache Rep. 2016. PMID: 26879878 Review.
Children and adolescents with sickle cell disease (SCD) have a high prevalence of recurrent headaches (24.0-43.9 %). Acute presentation with headache can be diagnostically challenging, as the clinician must consider evaluation of several potentially devastating cond …
Children and adolescents with sickle cell disease (SCD) have a high prevalence of recurrent headaches (24.0-43.9 %). Acute pre …
Healthcare utilization and hydroxyurea adherence in youth with sickle cell disease.
Badawy SM, Thompson AA, Holl JL, Penedo FJ, Liem RI. Badawy SM, et al. Pediatr Hematol Oncol. 2018 Aug-Sep;35(5-6):297-308. doi: 10.1080/08880018.2018.1505988. Epub 2019 Jan 12. Pediatr Hematol Oncol. 2018. PMID: 30636474 Clinical Trial.
BACKGROUND: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthcare utilization in this population, which could be mitigated with hydroxyurea therapy; however, adherence is suboptimal. ...More frequ …
BACKGROUND: Sickle cell disease (SCD) complications lead to poor health-related quality of life (HRQOL) and increased healthca …
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.
Brousseau DC, Scott JP, Badaki-Makun O, Darbari DS, Chumpitazi CE, Airewele GE, Ellison AM, Smith-Whitley K, Mahajan P, Sarnaik SA, Casper TC, Cook LJ, Dean JM, Leonard J, Hulbert ML, Powell EC, Liem RI, Hickey R, Krishnamurti L, Hillery CA, Nimmer M, Panepinto JA; Pediatric Emergency Care Applied Research Network (PECARN). Brousseau DC, et al. Blood. 2015 Oct 1;126(14):1651-7. doi: 10.1182/blood-2015-05-647107. Epub 2015 Jul 31. Blood. 2015. PMID: 26232172 Free PMC article. Clinical Trial.
Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We hypothesized that intravenous magnesium would shorten length of stay, decrease opioid use, and improve health-related quality of life (HRQL …
Magnesium, a vasodilator, anti-inflammatory, and pain reliever, could alter the pathophysiology of sickle cell pain crises. We …
236 results
Jump to page
Feedback